Evidence map›Paper›PMID 42796729›Full record

ArticlePathogens (Basel, Switzerland)2026

Risk Analysis from the Burden of Lyme Disease (BOLD) Study.

Kate Halsby, Alexandra Loew-Baselli, Anna Moniuszko-Malinowska, Franc Strle, Johan Sanmartin Berglund, Ye Tan, Brad D Gessner, Frederick J Angulo, Juanita Edwards, Andreas Pilz and 3 more

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kate HalsbyPfizer Ltd., Tadworth, Surrey KT20 7NS, UK.
Alexandra Loew-BaselliPfizer Corporation Austria GmbH, 1210 Vienna, Austria.ORCID 0000-0003-2924-0836
Anna Moniuszko-MalinowskaDepartment of Infectious Diseases and Neuroinfections, Medical University of Białystok, 15-540 Bialystok, Poland.ORCID 0000-0002-3994-8785
Franc StrleDepartment of Infectious Diseases, University Medical Centre Ljubljana, 1525 Ljubljana, Slovenia.ORCID 0000-0003-4163-0503
Johan Sanmartin BerglundDepartment of Health, Blekinge Institute of Technology, 371 79 Karlskrona, Sweden.ORCID 0000-0003-4312-2246
Ye TanPfizer Inc., Cambridge, MA 02139, USA.
Brad D GessnerPfizer Inc., Collegeville, PA 19426, USA.ORCID 0000-0002-6216-7194
Frederick J AnguloPfizer Inc., Collegeville, PA 19426, USA.
Juanita EdwardsPfizer Inc., Collegeville, PA 19426, USA.
Andreas PilzPfizer Corporation Austria GmbH, 1210 Vienna, Austria.ORCID 0000-0002-6394-3845
Elizabeth BegierPfizer Biopharma Group, D04 K7N3 Dublin, Ireland.ORCID 0000-0002-1287-5416
James H StarkPfizer Inc., Cambridge, MA 02139, USA.
On Behalf Of The Bold Study Group

Funding

Pfizer (United Kingdom)Valneva
6 · The paper itself

Abstract

Lyme borreliosis (LB) is endemic in many European countries. The prospective, epidemiological Burden of Lyme Disease (BOLD) study used unified case definitions to characterise LB burden in Europe. A retrospective case-control study was nested within the BOLD study to better understand LB risk factors. LB patients were evaluated at 14 healthcare practices in high-LB-incidence areas in six European countries: the Czech Republic, Germany, Poland, Slovakia, Slovenia, and Sweden between April 2021 and December 2022. Enrolled cases and age-group-matched controls were interviewed about potential risk factors, and multivariate regression analysis was used to analyse the responses. Patients with LB were more likely than matched controls to live in neighbourhoods with >50% woods, to have a garden that is composed of less than half dense trees, and to have a garden visited by wild animals. Characteristics associated with lower LB risk included being male and not having a bird feeder. The results are suggestive of risk associated with edge-of-the-forest areas, aligning with the previous literature on the increased risk of LB with forest fragmentation. Our findings support the importance of landscape structure and human-environment interactions in shaping LB risk.

Indexed as

Lyme DiseaseAdultAgedAnimalsCase-Control StudiesEuropeFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk Factorsburden of diseaseEuropeLyme borreliosisLyme diseaserisk factors

Identifiers

PMID42796729
PMCPMC13610116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.